The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat t...
The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed ...
The British health insurance and coverage provider is well-placed to invest in n...
Coya plans to file investigational new drug applications for COYA 302 in amyotro...
Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biol...
The FDA approved a CRISPR-based medicine to treat beta thalassemia, an inherited...
More than half of those responsible for registering clinical trials and reportin...
The federal government is overpaying Medicare Advantage plans more than ever, co...
As Congress hurtles toward another government funding deadline, lawmakers are st...
Novo Nordisk resumed shipments of the 1.7-milligram dose of its Wegovy weight lo...
Want to stay on top of the science and politics driving biotech today? Sign up t...
NIH director Monica Bertagnolli is at the center of the drug pricing debate over...
Cord blood banking sounds like a great idea — until you realize what it costs ba...
Can flu shots be reformulated in time for the 2024-25 flu season? Manufacturers ...
Only 17% of physicians surveyed felt they understood the FDA’s medical devices a...
Some doctors see private equity as the only way for their practices to survive —...
